Allogeneic Hematopoietic Cell Transplantation in Elderly Patients in a Latin American Country: Analysis of 11 Years of Data from the Brazilian Registry SBTMO/CIBMTR.

IF 3.6 3区 医学 Q2 HEMATOLOGY Transplantation and Cellular Therapy Pub Date : 2024-12-12 DOI:10.1016/j.jtct.2024.12.003
Fernando Barroso Duarte, Yhasmine Delles Oliveira Garcia, Nelson Hamerschlak, Vaneuza Araújo Moreira Funke, Maria Claudia Rodrigues Moreira, Alessandra Aparecida Paz, Jayr Schmidt Filho, Claudia Caceres Astigarraga, Roberto Luiz da Silva, Vinícius Campos de Molla, Alexandre Silvério, Vanderson Geraldo Rocha, João Victor Piccolo Feliciano, George Maurício Navarro Barros, Vergílio Antônio Rensi Colturato, Samir Kanaan Nabhan, João Samuel de Holanda Farias, Ana Carolina Arrais Maia, Ângelo Atalla, Ricardo Chiattone, Maria Cristina Martins de Almeida Macedo, Milton Alexandre Ferreira Aranha, Yana Augusta Novis Zogbi, Décio Lener, Rodolfo Daniel de Almeida Soares, Phillip Scheinberg, Rodolfo Froes Calixto, Gustavo Machado Teixeira, Marcos Paulo Colella, Celso Arrais Rodrigues, Anderson João Simione, Cinthya Corrêa da Silva, Paul J Martin, Mary E Flowers
{"title":"Allogeneic Hematopoietic Cell Transplantation in Elderly Patients in a Latin American Country: Analysis of 11 Years of Data from the Brazilian Registry SBTMO/CIBMTR.","authors":"Fernando Barroso Duarte, Yhasmine Delles Oliveira Garcia, Nelson Hamerschlak, Vaneuza Araújo Moreira Funke, Maria Claudia Rodrigues Moreira, Alessandra Aparecida Paz, Jayr Schmidt Filho, Claudia Caceres Astigarraga, Roberto Luiz da Silva, Vinícius Campos de Molla, Alexandre Silvério, Vanderson Geraldo Rocha, João Victor Piccolo Feliciano, George Maurício Navarro Barros, Vergílio Antônio Rensi Colturato, Samir Kanaan Nabhan, João Samuel de Holanda Farias, Ana Carolina Arrais Maia, Ângelo Atalla, Ricardo Chiattone, Maria Cristina Martins de Almeida Macedo, Milton Alexandre Ferreira Aranha, Yana Augusta Novis Zogbi, Décio Lener, Rodolfo Daniel de Almeida Soares, Phillip Scheinberg, Rodolfo Froes Calixto, Gustavo Machado Teixeira, Marcos Paulo Colella, Celso Arrais Rodrigues, Anderson João Simione, Cinthya Corrêa da Silva, Paul J Martin, Mary E Flowers","doi":"10.1016/j.jtct.2024.12.003","DOIUrl":null,"url":null,"abstract":"<p><p>This study analyzed recent changes in the utilization of allogeneic HCT for treatment of acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and myeloproliferative diseases (MPD) and the survival of HCT recipients ≥60 years of age in Brazil. This retrospective registry study included patients who received a first allogeneic HCT from any donor between 2012 and 2023. Of the 6657 patients, 444 (7%) were 60 years of age or older who received grafts from HLA-matched related (42%) or unrelated (20%) donors or HLA-haploidentical donors (32%). The proportion of HCT recipients 60 years of age or older increased gradually from 3.2% in 2012 to 16% in 2023 mostly due to the increased use of HLA-haploidentical donors since 2018. Overall survival (OS) at day 100 was 77%, and estimated OS at 12 months was 53% (95% CI, 48-58). OS at 12-months was higher for transplants during 2015-2017 (58%) and 2018-2020 (68%) compared to 2012-2014 (45%), but it did not differ for those during 2021-2023 (49%). Mortality with HLA-haploidentical donors (HR 2.35; 95%CI; 1.65-3.34 [p <0.001]) and cord blood donors (HR 4.68; 95%CI,1.29-16.9 [p= 0.01]) was higher than with HLA-matched related donors. Mortality was lower for transplants during the 2015-2020 period (HR 0.57; 95%CI, 0.34-0.96 [0.037]) than for those during 2012-2014.This study revealed a gradual increase in the use of allogeneic HCT in individuals aged 60 years and older in Brazil. While use of haploidentical donor has increased worldwide, its association with increased mortality in elderly population deserves caution.</p>","PeriodicalId":23283,"journal":{"name":"Transplantation and Cellular Therapy","volume":" ","pages":""},"PeriodicalIF":3.6000,"publicationDate":"2024-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Transplantation and Cellular Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jtct.2024.12.003","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

This study analyzed recent changes in the utilization of allogeneic HCT for treatment of acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and myeloproliferative diseases (MPD) and the survival of HCT recipients ≥60 years of age in Brazil. This retrospective registry study included patients who received a first allogeneic HCT from any donor between 2012 and 2023. Of the 6657 patients, 444 (7%) were 60 years of age or older who received grafts from HLA-matched related (42%) or unrelated (20%) donors or HLA-haploidentical donors (32%). The proportion of HCT recipients 60 years of age or older increased gradually from 3.2% in 2012 to 16% in 2023 mostly due to the increased use of HLA-haploidentical donors since 2018. Overall survival (OS) at day 100 was 77%, and estimated OS at 12 months was 53% (95% CI, 48-58). OS at 12-months was higher for transplants during 2015-2017 (58%) and 2018-2020 (68%) compared to 2012-2014 (45%), but it did not differ for those during 2021-2023 (49%). Mortality with HLA-haploidentical donors (HR 2.35; 95%CI; 1.65-3.34 [p <0.001]) and cord blood donors (HR 4.68; 95%CI,1.29-16.9 [p= 0.01]) was higher than with HLA-matched related donors. Mortality was lower for transplants during the 2015-2020 period (HR 0.57; 95%CI, 0.34-0.96 [0.037]) than for those during 2012-2014.This study revealed a gradual increase in the use of allogeneic HCT in individuals aged 60 years and older in Brazil. While use of haploidentical donor has increased worldwide, its association with increased mortality in elderly population deserves caution.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
本研究分析了巴西近期在使用异基因造血干细胞移植治疗急性髓性白血病(AML)、骨髓增生异常综合征(MDS)和骨髓增生性疾病(MPD)方面的变化以及年龄≥60 岁的造血干细胞移植受者的存活率。这项回顾性登记研究纳入了2012年至2023年间首次接受任何供体异基因造血干细胞移植的患者。在 6657 名患者中,有 444 人(7%)年龄在 60 岁或以上,他们接受的移植物来自 HLA 匹配的亲缘(42%)或非亲缘(20%)供体或 HLA 同种异体供体(32%)。60岁或以上的造血干细胞受者比例从2012年的3.2%逐渐增加到2023年的16%,这主要是由于2018年以来HLA-同种异体供体的使用增加。第100天的总生存率(OS)为77%,12个月的估计OS为53%(95% CI,48-58)。与2012-2014年(45%)相比,2015-2017年(58%)和2018-2020年(68%)的移植者12个月的OS更高,但2021-2023年(49%)的移植者OS没有差异。HLA-同种异体捐献者的死亡率(HR 2.35; 95%CI; 1.65-3.34 [p
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
7.00
自引率
15.60%
发文量
1061
审稿时长
51 days
期刊最新文献
Health-related values discussions with patients undergoing allogeneic and autologous stem cell transplant: Feasibility and acceptability of an early primary palliative care intervention. Incidence, risk factors, and outcomes of BK hemorrhagic cystitis in hematopoietic stem cell transplantation from HLA-matched and haploidentical donors with post-transplant cyclophosphamide. Letermovir for prevention of recurrent CMV in high-risk allogeneic hematopoietic cell transplant (HCT) recipients. Lipid levels increase to the normal range after nonmyeloablative hematopoietic cell transplantation for sickle cell disease. Pediatric Transplant and Cellular Therapy Consortium RESILIENT Conference on Pediatric Chronic Graft-Versus-Host Disease Survivorship After Hematopoietic Cell Transplantation: Part I. Phases of Chronic GVHD, Supportive Care, and Systemic Therapy Discontinuation.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1